Navigation Links
Watson Confirms Testim® Patent Challenge
Date:5/24/2012

PARSIPPANY, N.J., May 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim® 1%. Testim®1% is indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Auxilium Pharmaceuticals, Inc. and FCB I LLC filed suit against Watson on May 23, 2012 in the United States District Court for the District of New Jersey seeking to prevent Watson from commercializing its 1% testosterone gel product prior to the expiration of certain U.S. patents.  The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months from the date the plaintiffs received notice of Watson's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending March 31, 2012, Testim® had total U.S. sales of approximately $260 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology.  Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement 
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and Watson's Annual Report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Testim® is a registered trademark of Auxilium Pharmaceuticals, Inc.CONTACTS:  Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2020)... VALLEY, Calif. (PRWEB) , ... March 21, 2020 , ... ... new Health Screening Trailer Triage at Adventist Health Simi Valley. The ramp and platforms ... Angeles is considered to be an essential service as we install ramps that provide ...
(Date:3/19/2020)... ... March 19, 2020 , ... ... and effective as single food immunotherapy, according to research scheduled for presentation at ... it was cancelled due to the situation with coronavirus disease 2019 (COVID-19). ...
(Date:3/19/2020)... ... , ... As COVID-19 spreads across the nation, the Centers for Disease ... in some cases, self-quarantine to help stop the spread of the coronavirus. However, social ... issues. , Cindy Gipson, Ph.D., serves as the assistant director of intensive services ...
Breaking Medicine Technology:
(Date:3/28/2020)... VALLEY, N.Y. (PRWEB) , ... March 27, 2020 ... ... to protect workers and the public from the spread of the coronavirus. Operating ... Cuomo, crews are pressing forward with infrastructure renewal and environmental protection projects in ...
(Date:3/27/2020)... ... 27, 2020 , ... Justin P. Kubeck, MD of Ocean ... has been approved every year consecutively since 2016. Dr. Kubeck is board certified ... , Dr. Kubeck’s medical education began at Thomas Jefferson University. He then completed ...
(Date:3/22/2020)... ... , ... In partnership with UC Health, Cincy Shirts has created a new ... responders. The title comes from the English translation of “Juncta Juvant”, the City of ... Proceeds from the sale of the shirt will benefit the YMCA of Cincinnati Emergency ...
(Date:3/20/2020)... ... March 20, 2020 , ... CommunityMed Urgent Care , based in ... virtual waiting room lets patients present online, complete registration paperwork (including the latest COVID ... their turn, and get signaled that their clean exam room is ready. All ...
(Date:3/19/2020)... ... March 19, 2020 , ... ... to teach Executive Function, shares a free Student Learning Exercise: ExQ® Superpower ... parents and teachers are seeking resources to help with the immediate need for ...
Breaking Medicine News(10 mins):